FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by BIROCCIO, A.
Right arrow Articles by DEL BUFALO, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by BIROCCIO, A.
Right arrow Articles by DEL BUFALO, D.
(The FASEB Journal. 2000;14:652-660.)
© 2000 FASEB

Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line

ANNAMARIA BIROCCIO*, ANTONIO CANDILORO*, MARCELLA MOTTOLESE{dagger}, ORAZIO SAPORA{ddagger}, ADRIANA ALBINI§, GABRIELLA ZUPI* and DONATELLA DEL BUFALO*1

* Experimental Chemotherapy Laboratory, Regina Elena Cancer Institute, Rome, Italy;
{dagger} Pathology Department, Regina Elena Cancer Institute, Rome; Italy;
{ddagger} Comparative Toxicology Laboratory, Istituto Superiore di Sanità, Rome; Italy; and
§ Advanced Biotechnology Center, National Institute for Research on Cancer, Genova, Italy

1Correspondence: Experimental Chemotherapy Lab., Regina Elena Cancer Institute, Via delle Messi d’Oro N.156, 00158 Rome, Italy. E-mail: delbufalo{at}ifo.it

We have previously demonstrated that bcl-2 overexpression enhances the metastatic potential of the MCF7 ADR human breast cancer cell line resistant to adriamycin by inducing metastasis-associated properties. To further elucidate the relationship between bcl-2 expression and the metastatic potential of the MCF7 ADR line, we evaluated whether bcl-2 could be also involved in the modulation of the angiogenic phenotype. Four bcl-2-overexpressing clones, a control transfectant clone, and the MCF7 ADR parental line were used for in vitro and in vivo experiments. Bcl-2 overexpression enhanced the synthesis of the hypoxia-stimulated VEGF protein and mRNA. Northern blot analysis demonstrated an increased VEGF mRNA expression in bcl-2-overexpressing clones, and reverse transcription-polymerase chain reaction showed higher levels of the VEGF121 and VEGF165 mRNA isoforms, which are the most active in eliciting angiogenesis. When incorporated into matrigel, supernatants of bcl-2-transfected cells cultured under hypoxic conditions induced an increased angiogenic response in C57BL/6 mice compared with that of control clone. Tumors from bcl-2 transfectants demonstrated increased VEGF expression and neovascularization as compared to the parental line, whereas the apoptosis in in vivo xenografts was similar in control and bcl-2 transfectants. The effect of bcl-2 on angiogenesis was not mediated by p53 protein. These results demonstrate that bcl-2 and hypoxia can act synergistically to modulate VEGF expression and the in vivo angiogenic response in the MCF7 ADR line.—Biroccio, A., Candiloro, A., Mottolese, M., Sapora, O., Albini, A., Zupi, G., Del Bufalo, D. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line.


Key Words: in vivo matrigel assay • MCF7 ADR • metastasis




This article has been cited by other articles:


Home page
Cancer Res.Home page
C. D. Curtis, V. S. Likhite, I. X. McLeod, J. R. Yates, and A. M. Nardulli
Interaction of the Tumor Metastasis Suppressor Nonmetastatic Protein 23 Homologue H1 and Estrogen Receptor {alpha} Alters Estrogen-Responsive Gene Expression
Cancer Res., November 1, 2007; 67(21): 10600 - 10607.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
T. Kaneko, Z. Zhang, M. G. Mantellini, E. Karl, B. Zeitlin, M. Verhaegen, M. S. Soengas, M. Lingen, R. M. Strieter, G. Nunez, et al.
Bcl-2 Orchestrates a Cross-talk between Endothelial and Tumor Cells that Promotes Tumor Growth
Cancer Res., October 15, 2007; 67(20): 9685 - 9693.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
S. Giorgini, D. Trisciuoglio, C. Gabellini, M. Desideri, L. Castellini, C. Colarossi, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo
Modulation of bcl-xL in Tumor Cells Regulates Angiogenesis through CXCL8 Expression
Mol. Cancer Res., August 1, 2007; 5(8): 761 - 771.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
S. Anai, S. Goodison, K. Shiverick, Y. Hirao, B. D. Brown, and C. J. Rosser
Knock-down of Bcl-2 by antisense oligodeoxynucleotides induces radiosensitization and inhibition of angiogenesis in human PC-3 prostate tumor xenografts
Mol. Cancer Ther., January 1, 2007; 6(1): 101 - 111.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
L. Benimetskaya, K. Ayyanar, N. Kornblum, D. Castanotto, J. Rossi, S. Wu, J. Lai, B. D. Brown, N. Popova, P. Miller, et al.
Bcl-2 Protein in 518A2 Melanoma Cells In vivo and In vitro.
Clin. Cancer Res., August 15, 2006; 12(16): 4940 - 4948.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
D. Del Bufalo, L. Ciuffreda, D. Trisciuoglio, M. Desideri, F. Cognetti, G. Zupi, and M. Milella
Antiangiogenic Potential of the Mammalian Target of Rapamycin Inhibitor Temsirolimus
Cancer Res., June 1, 2006; 66(11): 5549 - 5554.
[Abstract] [Full Text] [PDF]


Home page
Mol. Biol. CellHome page
D. Trisciuoglio, A. Iervolino, G. Zupi, and D. Del Bufalo
Involvement of PI3K and MAPK Signaling in bcl-2-induced Vascular Endothelial Growth Factor Expression in Melanoma Cells
Mol. Biol. Cell, September 1, 2005; 16(9): 4153 - 4162.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. Yagi, D. McBurney, and W. E. Horton Jr.
Bcl-2 Positively Regulates Sox9-dependent Chondrocyte Gene Expression by Suppressing the MEK-ERK1/2 Signaling Pathway
J. Biol. Chem., August 26, 2005; 280(34): 30517 - 30525.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. Choi, K. Choi, E. N. Benveniste, Y.-S. Hong, J.-H. Lee, J. Kim, and K. Park
Bcl-2 Promotes Invasion and Lung Metastasis by Inducing Matrix Metalloproteinase-2
Cancer Res., July 1, 2005; 65(13): 5554 - 5560.
[Abstract] [Full Text] [PDF]


Home page
Jpn J Clin OncolHome page
W.-T. Chen, C.-J. Huang, M.-T. Wu, S.-F. Yang, Y.-C. Su, and C.-Y. Chai
Hypoxia-inducible Factor-1{alpha} is Associated with Risk of Aggressive Behavior and Tumor Angiogenesis in Gastrointestinal Stromal Tumor
Jpn. J. Clin. Oncol., April 1, 2005; 35(4): 207 - 213.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Milella, D. Trisciuoglio, T. Bruno, L. Ciuffreda, M. Mottolese, A. Cianciulli, F. Cognetti, U. Zangemeister-Wittke, D. Del Bufalo, and G. Zupi
Trastuzumab Down-Regulates Bcl-2 Expression and Potentiates Apoptosis Induction by Bcl-2/Bcl-XL Bispecific Antisense Oligonucleotides in HER-2Gene-Amplified Breast Cancer Cells
Clin. Cancer Res., November 15, 2004; 10(22): 7747 - 7756.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Fassina, R. Vene, M. Morini, S. Minghelli, R. Benelli, D. M. Noonan, and A. Albini
Mechanisms of Inhibition of Tumor Angiogenesis and Vascular Tumor Growth by Epigallocatechin-3-Gallate
Clin. Cancer Res., July 15, 2004; 10(14): 4865 - 4873.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
R. Shao, S. Bao, X. Bai, C. Blanchette, R. M. Anderson, T. Dang, M. L. Gishizky, J. R. Marks, and X.-F. Wang
Acquired Expression of Periostin by Human Breast Cancers Promotes Tumor Angiogenesis through Up-Regulation of Vascular Endothelial Growth Factor Receptor 2 Expression
Mol. Cell. Biol., May 1, 2004; 24(9): 3992 - 4003.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
D. Trisciuoglio, A. Iervolino, A. Candiloro, G. Fibbi, M. Fanciulli, U. Zangemeister-Wittke, G. Zupi, and D. Del Bufalo
bcl-2 Induction of Urokinase Plasminogen Activator Receptor Expression in Human Cancer Cells through Sp1 Activation: INVOLVEMENT OF ERK1/ERK2 ACTIVITY
J. Biol. Chem., February 20, 2004; 279(8): 6737 - 6745.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
G. Tortora, R. Caputo, V. Damiano, R. Caputo, T. Troiani, B. M. Veneziani, S. De Placido, A. R. Bianco, U. Zangemeister-Wittke, and F. Ciardiello
Combined Targeted Inhibition of bcl-2, bcl-XL, Epidermal Growth Factor Receptor, and Protein Kinase A Type I Causes Potent Antitumor, Apoptotic, and Antiangiogenic Activity
Clin. Cancer Res., February 1, 2003; 9(2): 866 - 871.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, G. Allevi, G. Bolsi, S. Aguggini, A. Brunelli, E. Betri, D. Generali, et al.
Changes in Microvessel Density As Assessed by CD34 Antibodies after Primary Chemotherapy in Human Breast Cancer
Clin. Cancer Res., June 1, 2002; 8(6): 1816 - 1821.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
F. Ciardiello and G. Tortora
Inhibition of bcl-2 as cancer therapy
Ann. Onc., April 1, 2002; 13(4): 501 - 502.
[Full Text] [PDF]


Home page
JCOHome page
A. J. Guidi, D. A. Berry, G. Broadwater, B. Helmchen, I. J. Bleiweiss, D. R. Budman, I. C. Henderson, L. Norton, and D. F. Hayes
Association of Angiogenesis and Disease Outcome in Node-Positive Breast Cancer Patients Treated With Adjuvant Cyclophosphamide, Doxorubicin, and Fluorouracil: A Cancer and Leukemia Group B Correlative Science Study From Protocols 8541/8869
J. Clin. Oncol., February 1, 2002; 20(3): 732 - 742.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. E. Nör, J. Christensen, J. Liu, M. Peters, D. J. Mooney, R. M. Strieter, and P. J. Polverini
Up-Regulation of Bcl-2 in Microvascular Endothelial Cells Enhances Intratumoral Angiogenesis and Accelerates Tumor Growth
Cancer Res., March 1, 2001; 61(5): 2183 - 2188.
[Abstract] [Full Text]


Home page
Clin. Cancer Res.Home page
K. Inoue, J. W. Slaton, T. Karashima, C. Yoshikawa, T. Shuin, P. Sweeney, R. Millikan, and C. P. N. Dinney
The Prognostic Value of Angiogenesis Factor Expression for Predicting Recurrence and Metastasis of Bladder Cancer after Neoadjuvant Chemotherapy and Radical Cystectomy
Clin. Cancer Res., December 1, 2000; 6(12): 4866 - 4873.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2000 by The Federation of American Societies for Experimental Biology.